ELMED Probiotics has raised $2.7 million in investment capital, marking a significant milestone for the science-driven microbiome company. Founded in 2019 and headquartered in Hyderabad, India, ELMED Life Sciences is dedicated to advancing the Global One Health approach, integrating solutions across Human Health, Animal Health, and Agriculture. The company specializes in partnering with global healthcare and agri-biotech firms for contract manufacturing, research, and innovative probiotic development.
This funding round is poised to accelerate ELMED's strategic growth initiatives. The capital infusion is expected to support the expansion of its research and development capabilities, further enhance its state-of-the-art manufacturing facility, and strengthen its market presence in the rapidly evolving microbiome sector. The investment underscores confidence in ELMED's unique approach to sustainable microbiome solutions.
ELMED Probiotics maintains a strong focus on Agrobiotics, developing next-generation probiotics designed to support gut health, improve livestock performance, and enhance soil vitality and crop productivity. This integrated ecosystem impact is central to their mission. Their manufacturing facility is ISO 22000:2018, HACCP, WHO-GMP certified, and US-FDA registered, capable of producing multiple dosage forms including capsules, sachets, syrups, drops, and oral suspensions, all tailored to meet global regulatory standards.
Looking ahead, ELMED Probiotics plans to leverage this investment to continue its trajectory of innovation and expansion. The company aims to solidify its position as a leader in microbiome science, driving sustainable solutions that benefit health and agriculture worldwide.
.png&w=3840&q=75)
